Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% | 0.00% | +79.28% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 129M |
---|---|---|---|---|---|
Net income 2024 * | -104M | Net income 2025 * | -107M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.8
x | P/E ratio 2025 * |
-4.05
x | Employees | 138 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.11% |
Latest transcript on NGM Biopharmaceuticals, Inc.
1 day | -1.28% | ||
Current month | -3.14% | ||
1 month | -0.65% | ||
3 months | +18.46% | ||
6 months | +69.60% | ||
Current year | +79.28% |
Managers | Title | Age | Since |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 21-06-07 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | -.--% | - |
1st Jan change | Capi. | |
---|---|---|
+79.28% | 129M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.00% | 22.19B | |
-16.16% | 21.33B | |
-7.29% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- NGM Stock